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In order to allow clarity and consistency in pharmacology, there is a need for a comprehensive organisation and presentation of the targets of drugs. This is the philosophy of the IUPHAR/BPS Guide to PHARMACOLOGY presented on the online free access database (<https://www.guidetopharmacology.org/>). This database is supported by the British Pharmacological Society (BPS), the International Union of Basic and Clinical Pharmacology (IUPHAR), the University of Edinburgh and previously the Wellcome Trust. Data included in the Guide to PHARMACOLOGY are derived in large part from interactions with the subcommittees of the Nomenclature Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR). A major influence on the development of the database was Tony Harmar (1951‐2014), who worked with a passion to establish the curators as a team of highly informed and informative individuals, with a focus on high‐quality data input, ensuring a suitably validated dataset. The Editors of the Concise Guide have compiled the individual records, in concert with the team of Curators, drawing on the expert knowledge of these latter subcommittees. The tables allow an indication of the status of the nomenclature for the group of targets listed, usually previously published in Pharmacological Reviews. In the absence of an established subcommittee, advice from several prominent, independent experts has generally been obtained to produce an authoritative consensus on nomenclature, which attempts to fit in within the general guidelines from NC‐IUPHAR. This current edition, the Concise Guide to PHARMACOLOGY 2019/20, is the latest snapshot of the database in print form, following on from the Concise Guide to PHARMACOLOGY 2017/18. It contains data drawn from the online database as a rapid overview of the major pharmacological targets. Thus, there are many fewer targets presented in the Concise Guide compared to the online database. The priority for inclusion in the Concise Guide is the presence of quantitative pharmacological data for human proteins. This means that often orphan family members are not presented in the Concise Guide, although structural information is available on the online database. The organisation of the data is tabular (where appropriate) with a standardised format, where possible on a single page, intended to aid understanding of, and comparison within, a particular target group. The Concise Guide is intended as an initial resource, with links to additional reviews and resources for greater depth and information. Pharmacological and structural data focus primarily on human gene products, wherever possible, with links to HGNC gene nomenclature and UniProt IDs. In a few cases, where data from human proteins are limited, data from other species are indicated. Pharmacological tools listed are prioritised on the basis of selectivity and availability. That is, agents (agonists, antagonists, inhibitors, activators, etc.) are included where they are both available (by donation or from commercial sources, now or in the near future) AND the most selective. The Concise Guide is divided into seven sections, which comprise pharmacological targets of similar structure/function. These are G protein‐coupled receptors, ion channels (combining previous records of ligand‐gated, voltage‐gated and other ion channels), catalytic receptors, nuclear hormone receptors, enzymes, transporters and other protein targets. We hope that the Concise Guide will provide for researchers, teachers and students a state‐of‐the art source of accurate, curated information on the background to their work that they will use in the Introductions to their Research Papers or Reviews, or in supporting their teaching and studies. We recommend that any citations to information in the Concise Guide are presented in the following format: Alexander SPH et al. (2019). The Concise Guide to PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. Br J Pharmacol 176: S1--S20. In this overview are listed protein targets of pharmacological interest, which are not G protein‐coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors, transporters or enzymes.
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### Overview {#bph14747-sec-0014}

Adiponectin receptors (**provisional nomenclature**, <http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00500000270960>) respond to the 30 kDa complement‐related protein hormone adiponectin (also known as <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13633>: adipocyte, C1q and collagen domain‐containing protein; ACRP30, adipose most abundant gene transcript 1; apM‐1; gelatin‐binding protein: <http://www.uniprot.org/uniprot/Q15848>) originally cloned from adipocytes \[<http://www.ncbi.nlm.nih.gov/pubmed/8619847?dopt=AbstractPlus>\]. Although sequence data suggest 7TM domains, immunological evidence indicates that, contrary to typical 7TM topology, the carboxyl terminus is extracellular, while the amino terminus is intracellular \[<http://www.ncbi.nlm.nih.gov/pubmed/12802337?dopt=AbstractPlus>\]. Signalling through these receptors appears to avoid G proteins; modelling based on the crystal structures of the adiponectin receptors suggested ceramidase acivity, which would make these the first in a new family of catalytic receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/25855295?dopt=AbstractPlus>\]. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=649><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=650>HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24040>, <http://www.uniprot.org/uniprot/Q96A54><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24041>, <http://www.uniprot.org/uniprot/Q86V24>Rank order of potency<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3727> (<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13633>, <http://www.uniprot.org/uniprot/Q15848>) \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3726> (<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13633>, <http://www.uniprot.org/uniprot/Q15848>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3727> (<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13633>, <http://www.uniprot.org/uniprot/Q15848>) = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3726> (<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13633>, <http://www.uniprot.org/uniprot/Q15848>)

### Comments {#bph14747-sec-0015}

T‐Cadherin (<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1753>, <http://www.uniprot.org/uniprot/P55290>) has also been suggested to be a receptor for (hexameric) adiponectin \[<http://www.ncbi.nlm.nih.gov/pubmed/15210937?dopt=AbstractPlus>\].

### Further reading on Adiponectin receptors {#bph14747-sec-0016}

Fisman EZ *et al*. (2014) Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? *Cardiovasc Diabetol* **13**: 103 \[<https://www.ncbi.nlm.nih.gov/pubmed/24957699?dopt=AbstractPlus>\]

Okada‐Iwabu M *et al*. (2018) Structure and function analysis of adiponectin receptors toward development of novel antidiabetic agents promoting healthy longevity. *Endocr J* **65**: 971‐977 \[<https://www.ncbi.nlm.nih.gov/pubmed/30282888>\]

Ruan H *et al*. (2016) Adiponectin signaling and function in insulin target tissues. *J Mol Cell Biol* **8**: 101‐9 \[<https://www.ncbi.nlm.nih.gov/pubmed/26993044?dopt=AbstractPlus>\]

Wang Y *et al*. (2017) Cardiovascular Adiponectin Resistance: The Critical Role of Adiponectin Receptor Modification. *Trends Endocrinol. Metab.* **28**: 519‐530 \[<https://www.ncbi.nlm.nih.gov/pubmed/28473178?dopt=AbstractPlus>\]

Zhao L *et al*. (2014) Adiponectin and insulin cross talk: the microvascular connection. *Trends Cardiovasc. Med.* **24**: 319‐24 \[<https://www.ncbi.nlm.nih.gov/pubmed/25220977?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=853> {#bph14747-sec-0017}
---------------------------------------------------------------------------

### Overview {#bph14747-sec-0018}

Coagulation as a process is interpreted as a mechanism for reducing excessive blood loss through the generation of a gel‐like clot local to the site of injury. The process involves the activation, adhesion (see <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=760>), degranulation and aggregation of platelets, as well as proteins circulating in the plasma. The coagulation cascade involves multiple proteins being converted to more active forms from less active precursors, typically through proteolysis (see <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=759&familyType=ENZYME>). Listed here are the components of the coagulation cascade targetted by agents in current clinical usage. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2606><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2632>HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3542>, <http://www.uniprot.org/uniprot/P12259><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3546>, <http://www.uniprot.org/uniprot/P00451><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:775>, <http://www.uniprot.org/uniprot/P01008>Selective activators----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4214> (p*K* ~d~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/23598032?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6819> (p*K* ~d~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/12383040?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6803> \[<http://www.ncbi.nlm.nih.gov/pubmed/3744129?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6804> \[<http://www.ncbi.nlm.nih.gov/pubmed/8137606?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19398784?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6811> \[<http://www.ncbi.nlm.nih.gov/pubmed/7667822?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6846> \[<http://www.ncbi.nlm.nih.gov/pubmed/7528134?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6788> (Antithrombotic effect thought to occur via inhibition of factors Va and VIIIa) \[<http://www.ncbi.nlm.nih.gov/pubmed/11714212?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11463021?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6788> (Antithrombotic effect thought to occur via inhibition of factors Va and VIIIa) \[<http://www.ncbi.nlm.nih.gov/pubmed/11714212?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11463021?dopt=AbstractPlus>\]--

### Further reading on Blood coagulation components {#bph14747-sec-0019}

Astermark J. (2015) FVIII inhibitors: pathogenesis and avoidance. *Blood* **125**: 2045‐51 \[<https://www.ncbi.nlm.nih.gov/pubmed/25712994?dopt=AbstractPlus>\]

Girolami A *et al*. (2017) New clotting disorders that cast new light on blood coagulation and may play a role in clinical practice. *J. Thromb. Thrombolysis* **44**: 71‐75 \[<https://www.ncbi.nlm.nih.gov/pubmed/28251495?dopt=AbstractPlus>\]

Rana K *et al*. (2016) Blood flow and mass transfer regulation of coagulation. *Blood Rev.* **30**: 357‐68 \[<https://www.ncbi.nlm.nih.gov/pubmed/27133256?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=867> {#bph14747-sec-0020}
---------------------------------------------------------------------------

### Overview {#bph14747-sec-0021}

Bromodomains bind proteins with acetylated lysine residues, such as histones, to regulate gene transcription. Listed herein are examples of bromodomain‐containing proteins for which sufficient pharmacology exists. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2721><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2722><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2734><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2738><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2740>HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:962>, <http://www.uniprot.org/uniprot/Q9UIF9><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:963>, <http://www.uniprot.org/uniprot/Q9UIF8><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2348>, <http://www.uniprot.org/uniprot/Q92793><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30064>, <http://www.uniprot.org/uniprot/Q86U86><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11100>, <http://www.uniprot.org/uniprot/P51532>Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8233> (p*K* ~d~ 6.6) \[[85](#bph14747-bib-0085){ref-type="ref"}\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8233> (Binding) (p*K* ~d~ 6.9) \[[85](#bph14747-bib-0085){ref-type="ref"}\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8236> (p*K* ~d~ 6.8) \[[84](#bph14747-bib-0084){ref-type="ref"}\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7915> (Binding) (p*K* ~d~ 7.3) \[[95](#bph14747-bib-0095){ref-type="ref"}\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7915> (Binding) (p*K* ~d~ 7.1) \[[95](#bph14747-bib-0095){ref-type="ref"}\]

### Further reading on Non‐enzymatic BRD containing proteins {#bph14747-sec-0022}

Fujisawa T *et al*. (2017) Functions of bromodomain‐containing proteins and their roles in homeostasis and cancer. *Nat. Rev. Mol. Cell Biol.* **18**: 246‐262 \[<https://www.ncbi.nlm.nih.gov/pubmed/28053347?dopt=AbstractPlus>\]

Myrianthopoulos V & Mikros E. (2019) From bench to bedside, via desktop. Recent advances in the application of cutting‐edge in silico tools in the research of drugs targeting bromodomain modules. *Biochem Pharmacol* **159**: 40‐51 \[<https://www.ncbi.nlm.nih.gov/pubmed/30414936>\]

Nicholas DA *et al*. (2017) BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer. *Cell. Mol. Life Sci.* **74**: 231‐243 \[<https://www.ncbi.nlm.nih.gov/pubmed/27491296?dopt=AbstractPlus>\]

Ramadoss M & Mahadevan V. (2018) Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors. *Drug Discov Today* **23**: 76‐89 \[<https://www.ncbi.nlm.nih.gov/pubmed/28943305>\]

Yang CY *et al*. (2019) Small‐molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins ‐ A review. *Drug Discov Today Technol* **31**: 43‐51 \[<https://www.ncbi.nlm.nih.gov/pubmed/31200858>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=911> {#bph14747-sec-0023}
---------------------------------------------------------------------------

### Overview {#bph14747-sec-0024}

Transthyretin (TTR) is a homo‐tetrameric protein which transports thyroxine in the plasma and cerebrospinal fluid and retinol (vitamin A) in the plasma. Many disease causing mutations in the protein have been reported, many of which cause complex dissociation and protein mis‐assembly and deposition of toxic aggregates amyloid fibril formation \[<http://www.ncbi.nlm.nih.gov/pubmed/23716704?dopt=AbstractPlus>\]. These amyloidogenic mutants are linked to the development of pathological amyloidoses, including familial amyloid polyneuropathy (FAP) \[<http://www.ncbi.nlm.nih.gov/pubmed/12978172?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8894411?dopt=AbstractPlus>\], familial amyloid cardiomyopathy (FAC) \[<http://www.ncbi.nlm.nih.gov/pubmed/9017939?dopt=AbstractPlus>\], amyloidotic vitreous opacities, carpal tunnel syndrome \[<http://www.ncbi.nlm.nih.gov/pubmed/10403814?dopt=AbstractPlus>\] and others. In old age, non‐mutated TTR can also form pathological amyloid fibrils \[<http://www.ncbi.nlm.nih.gov/pubmed/7016817?dopt=AbstractPlus>\]. Pharmacological intervention to reduce or prevent TTR dissociation is being pursued as a theapeutic strategy. To date one small molecule kinetic stabilising molecule (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8378>) has been approved for FAP, and is being evaluated in clinical trials for other TTR amyloidoses. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2851>Common abbreviationTTRHGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12405>, <http://www.uniprot.org/uniprot/P02766>

### Further reading on Carrier proteins {#bph14747-sec-0025}

Adams D *et al*. (2019) Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. *Nat Rev Neurol* **15**: 387‐404 \[<https://www.ncbi.nlm.nih.gov/pubmed/31209302>\]

Dellière S *et al*. (2017) Is transthyretin a good marker of nutritional status? *Clin Nutr* **36**: 364‐370 \[<https://www.ncbi.nlm.nih.gov/pubmed/27381508?dopt=AbstractPlus>\]

Galant NJ *et al*. (2017) Transthyretin amyloidosis: an under‐recognized neuropathy and cardiomyopathy. *Clin. Sci.* **131**: 395‐409 \[<https://www.ncbi.nlm.nih.gov/pubmed/28213611?dopt=AbstractPlus>\]

Yokoyama T & Mizuguchi M. (2018) Inhibition of the Amyloidogenesis of Transthyretin by Natural Products and Synthetic Compounds. *Biol Pharm Bull* **41**: 979‐984 \[<https://www.ncbi.nlm.nih.gov/pubmed/29962408>\]

Ruberg FL *et al*. (2019) Transthyretin Amyloid Cardiomyopathy: JACC State‐of‐the‐Art Review. *J Am Coll Cardiol* **73**: 2872‐2891 \[<https://www.ncbi.nlm.nih.gov/pubmed/31171094>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=852> {#bph14747-sec-0026}
---------------------------------------------------------------------------

### Overview {#bph14747-sec-0027}

Cluster of differentiation refers to an attempt to catalogue systematically a series of over 300 cell‐surface proteins associated with immunotyping. Many members of the group have identified functions as enzymes (for example, see <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1232>) or receptors (for example, see <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2441>). Many CDs are targeted for therapeutic gain using antibodies for the treatment of proliferative disorders. A full listing of all the Clusters of Differentiation proteins is not possible in the Guide to PHARMACOLOGY; listed herein are selected members of the family targeted for therapeutic gain. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2600><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2742><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2917><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628>)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2601>Common abbreviation--------SIGLEC‐3HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1639>, <http://www.uniprot.org/uniprot/P06729><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1674>, <http://www.uniprot.org/uniprot/P07766><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1691>, <http://www.uniprot.org/uniprot/P30203><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7315>, <http://www.uniprot.org/uniprot/P11836><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1659>, <http://www.uniprot.org/uniprot/P20138>Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6787> \[<http://www.ncbi.nlm.nih.gov/pubmed/11970990?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12089534?dopt=AbstractPlus>\]--------Antibodies--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7385> (Binding) \[<http://www.ncbi.nlm.nih.gov/pubmed/20190561?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6889> (Binding) \[<http://www.ncbi.nlm.nih.gov/pubmed/3105134?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8458> (Binding) \[<http://www.ncbi.nlm.nih.gov/pubmed/8436176?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6778> (Binding) (p*K* ~d~ 9.9) \[[52](#bph14747-bib-0052){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6780> (Binding) (p*K* ~d~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/15102696?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6777> (Binding), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6941> (Binding) \[<http://www.ncbi.nlm.nih.gov/pubmed/21378274?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23537278?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6781> (Binding)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7983> (Binding) (p*K* ~d~ ∼10) \[<http://www.ncbi.nlm.nih.gov/pubmed/1458463?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6775> (Binding) \[<http://www.ncbi.nlm.nih.gov/pubmed/10720144?dopt=AbstractPlus>\] Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2602><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2744><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2745><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2743>)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2760>)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2918>Common abbreviation------CTLA‐4PD‐1--HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1804>, <http://www.uniprot.org/uniprot/P31358><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1700>, <http://www.uniprot.org/uniprot/P33681><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1705>, <http://www.uniprot.org/uniprot/P42081><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2505>, <http://www.uniprot.org/uniprot/P16410><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8760>, <http://www.uniprot.org/uniprot/Q15116><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19319>, <http://www.uniprot.org/uniprot/Q9UGN4>Endogenous ligands--------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9606> (<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17635>, <https://www.uniprot.org/uniprot/Q9NZQ7>) (Binding)--Selective inhibitors--abatacept (p*K* ~d~ ∼7.9) \[[51](#bph14747-bib-0051){ref-type="ref"}, [103](#bph14747-bib-0103){ref-type="ref"}\]abatacept (p*K*d ∼7.9) \[<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6891>\], belatacept \[[44](#bph14747-bib-0044){ref-type="ref"}\]------Antibodiesalemtuzumab (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6770>, [86](#bph14747-bib-0086){ref-type="ref"}\]----ipilimumab (Binding) (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6888>) \[[30](#bph14747-bib-0030){ref-type="ref"}\], tremelimumab (Binding) (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8462>\]pembrolizumab (Binding) (p*K* ~d~ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7499> (Binding) (p<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7499> ~d~ 9.1) \[<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7335>\]--

### Comments {#bph14747-sec-0028}

The endogenous ligands for human PD‐1 are programmed cell death 1 ligand 1 (PD‐L1 *aka* <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7693> (<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17635>, <http://www.uniprot.org/uniprot/Q9NZQ7>)) and programmed cell death 1 ligand 2 (PD‐L2; <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18731>). These ligands are cell surface peptides, normally involved in immune system regulation. Expression of PD‐1 by cancer cells induces immune tolerance and evasion of immune system attack. Anti‐PD‐1 monoclonal antibodies are used to induce immune checkpoint blockade as a therapeutic intervention in cancer, effectively re‐establishing immune vigilance. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7499> was the first anti‐PD‐1 antibody to be approved by the US FDA.

### Further reading on CD molecules {#bph14747-sec-0029}

Gabius HJ *et al*. (2015) The glycobiology of the CD system: a dictionary for translating marker designations into glycan/lectin structure and function. *Trends Biochem. Sci.* **40**: 360‐76 \[<https://www.ncbi.nlm.nih.gov/pubmed/25981696?dopt=AbstractPlus>\]

Vosoughi T *et al*. (2019) CD markers variations in chronic lymphocytic leukemia: New insights into prognosis. *J Cell Physiol*. **234**: 19420‐39 \[<https://www.ncbi.nlm.nih.gov/pubmed/31049958>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=902> {#bph14747-sec-0030}
---------------------------------------------------------------------------

### Overview {#bph14747-sec-0031}

Methyllysine reader proteins bind to methylated proteins, such as histones, allowing regulation of gene expression. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2830>HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23035>, <http://www.uniprot.org/uniprot/Q96JM7>Selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8232> \[<http://www.ncbi.nlm.nih.gov/pubmed/23292653?dopt=AbstractPlus>\]

### Further reading on Methyllysine reader proteins {#bph14747-sec-0032}

Daskalaki MG *et al*. (2018) Histone methylation and acetylation in macrophages as a mechanism for regulation of inflammatory responses. *J Cell Physiol*. **233**: 6495‐9507 \[<https://www.ncbi.nlm.nih.gov/pubmed/29574768>\]

Furuya K *et al*. (2019) Epigenetic interplays between DNA demethylation and histone methylation for protecting oncogenesis. *J Biochem*. **165**: 297‐299 \[<https://www.ncbi.nlm.nih.gov/pubmed/30605533>\]

Levy D. (2019) Lysine methylation signaling of non‐histone proteins in the nucleus. *Cell Mol Life Sci* **76**: 2873‐83 \[<https://www.ncbi.nlm.nih.gov/pubmed/31123776>\]

Li J *et al*. (2019) Understanding histone H3 lysine 36 methylation and its deregulation in disease. *Cell Mol Life Sci* in press \[<https://www.ncbi.nlm.nih.gov/pubmed/31147750>\]

Shafabakhsh R *et al*. (2019) Role of histone modification and DNA methylation in signaling pathways involved in diabetic retinopathy. *J Cell Physiol.* **234**: 7839‐7846 \[<https://www.ncbi.nlm.nih.gov/pubmed/30515789>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=783> {#bph14747-sec-0033}
---------------------------------------------------------------------------

### Overview {#bph14747-sec-0034}

Fatty acid‐binding proteins are low molecular weight (100‐130 aa) chaperones for long chain fatty acids, fatty acyl CoA esters, eicosanoids, retinols, retinoic acids and related metabolites and are usually regarded as being responsible for allowing the otherwise hydrophobic ligands to be mobile in aqueous media. These binding proteins may perform functions extracellularly (*e.g.* in plasma) or transport these agents; to the nucleus to interact with nuclear receptors (principally PPARs and retinoic acid receptors <http://www.ncbi.nlm.nih.gov/pubmed/17882463?dopt=AbstractPlus>\]) or for interaction with metabolic enzymes. Although sequence homology is limited, crystallographic studies suggest conserved 3D structures across the group of binding proteins. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2531><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2532><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2533><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2534><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2535>HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3555>, <http://www.uniprot.org/uniprot/P07148><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3556>, <http://www.uniprot.org/uniprot/P12104><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3557>, <http://www.uniprot.org/uniprot/P05413><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3559>, <http://www.uniprot.org/uniprot/P15090><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3560>, <http://www.uniprot.org/uniprot/Q01469>Rank order of potency<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3377>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049> \[<http://www.ncbi.nlm.nih.gov/pubmed/7929039?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3377> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055>,<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049> \[<http://www.ncbi.nlm.nih.gov/pubmed/7929039?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3377>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> \[<http://www.ncbi.nlm.nih.gov/pubmed/7929039?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3377>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> \[<http://www.ncbi.nlm.nih.gov/pubmed/7929039?dopt=AbstractPlus>\]--Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7186> (p*K* ~i~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/18533710?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2662> (p*K* ~i~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/18533710?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6736> (p*K* ~i~ 5.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/19754198?dopt=AbstractPlus>\] -- Mouse------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8797> (p*K* ~i~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/17502136?dopt=AbstractPlus>\]Selective inhibitors------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8788> (p*K* ~i~ \>9) \[<http://www.ncbi.nlm.nih.gov/pubmed/21481589?dopt=AbstractPlus>\]--CommentsA broader substrate specificity than other FABPs, binding two fatty acids per protein \[<http://www.ncbi.nlm.nih.gov/pubmed/9054409?dopt=AbstractPlus>\].Crystal structure of the rat FABP2 \[<http://www.ncbi.nlm.nih.gov/pubmed/2671390?dopt=AbstractPlus>\].Crystal structure of the human FABP3 \[<http://www.ncbi.nlm.nih.gov/pubmed/7922029?dopt=AbstractPlus>\].--Crystal structure of the human FABP5 \[<http://www.ncbi.nlm.nih.gov/pubmed/10493790?dopt=AbstractPlus>\]. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2536><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2537><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2544><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2538><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2584>HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3561>, <http://www.uniprot.org/uniprot/P51161><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3562>, <http://www.uniprot.org/uniprot/O15540><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9117>, <http://www.uniprot.org/uniprot/P02689><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3563>, <http://www.uniprot.org/uniprot/Q0Z7S8><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:34524>, <http://www.uniprot.org/uniprot/A6NFH5>CommentsAble to transport bile acids \[<http://www.ncbi.nlm.nih.gov/pubmed/23603607?dopt=AbstractPlus>\].Crystal structure of the human FABP7 \[<http://www.ncbi.nlm.nih.gov/pubmed/10854433?dopt=AbstractPlus>\].*In silico* modelling suggests that PMP2/FABP8 can bind both fatty acids and cholesterol \[<http://www.ncbi.nlm.nih.gov/pubmed/20421974?dopt=AbstractPlus>\].---- Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2546><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2547><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2548><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2549><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2550><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2551>HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9919>, <http://www.uniprot.org/uniprot/P09455><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9920>, <http://www.uniprot.org/uniprot/P50120><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9921>, <http://www.uniprot.org/uniprot/P10745><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9922>, <http://www.uniprot.org/uniprot/P02753><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15847>, <http://www.uniprot.org/uniprot/P82980><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30316>, <http://www.uniprot.org/uniprot/Q96R05>Rank order of potency--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3377> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> \[<http://www.ncbi.nlm.nih.gov/pubmed/10852718?dopt=AbstractPlus>\]--------Inhibitors------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8792> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/24835984?dopt=AbstractPlus>\]---- Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2545><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2529><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2530>HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10024>, <http://www.uniprot.org/uniprot/P12271><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2338>, <http://www.uniprot.org/uniprot/P29762><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2339>, <http://www.uniprot.org/uniprot/P29373>Rank order of potency<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6669>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6670> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6673>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6671>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6672>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2350>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4053> \[<http://www.ncbi.nlm.nih.gov/pubmed/9541407?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2645> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3377> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> \[<http://www.ncbi.nlm.nih.gov/pubmed/10852718?dopt=AbstractPlus>\]--

### Comments {#bph14747-sec-0035}

Although not tested at all FABPs, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6735> exhibits high affinity for FABP4 (pIC50 8.8) compared to FABP3 or FABP5 (pIC50 \<6.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/17554340?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17502136?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6736> is reported to interfere with FABP4 action \[<http://www.ncbi.nlm.nih.gov/pubmed/19754198?dopt=AbstractPlus>\]. Ibuprofen displays some selectivity for FABP4 (pIC~50~ 5.5) relative to FABP3 (pIC~50~ 3.5) and FABP5 (pIC~50~ 3.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/24248795?dopt=AbstractPlus>\]. Fenofibric acid displays some selectivity for FABP5 (pIC~50~ 5.5) relative to FABP3 (pIC~50~ 4.5) and FABP4 (pIC~50~ 4.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/24248795?dopt=AbstractPlus>\]. Multiple pseudogenes for the FABPs have been identified in the human genome.

### Further reading on Fatty acid‐binding proteins {#bph14747-sec-0036}

Gajda AM *et al*. (2015) Enterocyte fatty acid‐binding proteins (FABPs): different functions of liver and intestinal FABPs in the intestine. *Prostaglandins Leukot. Essent. Fatty Acids* **93**: 9‐16 \[<https://www.ncbi.nlm.nih.gov/pubmed/25458898?dopt=AbstractPlus>\]

Glatz JF. (2015) Lipids and lipid binding proteins: a perfect match. *Prostaglandins Leukot Essent Fatty Acids* **93**: 45‐9 \[<https://www.ncbi.nlm.nih.gov/pubmed/25154384?dopt=AbstractPlus>\]

Hotamisligil GS *et al*. (2015) Metabolic functions of FABPs--mechanisms and therapeutic implications. *Nat Rev Endocrinol* **11**: 592‐605 \[<https://www.ncbi.nlm.nih.gov/pubmed/26260145?dopt=AbstractPlus>\]

Matsumata M *et al*. (2016) Fatty acid binding proteins and the nervous system: Their impact on mental conditions. *Neurosci. Res.* **102**: 47‐55 \[<https://www.ncbi.nlm.nih.gov/pubmed/25205626?dopt=AbstractPlus>\]

Osumi T *et al*. (2016) Heart lipid droplets and lipid droplet‐binding proteins: Biochemistry, physiology, and pathology. *Exp. Cell Res.* **340**: 198‐204 \[<https://www.ncbi.nlm.nih.gov/pubmed/26524506?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=914> {#bph14747-sec-0037}
---------------------------------------------------------------------------

### Overview {#bph14747-sec-0038}

The canonical Notch signalling pathway has four type I transmembrane Notch receptors (Notch1‐4) and five ligands (DLL1, 2 and 3, and Jagged 1‐2). Each member of this highly conserved receptor family plays a unique role in cell‐fate determination during embryogenesis, differentiation, tissue patterning, proliferation and cell death \[<http://www.ncbi.nlm.nih.gov/pubmed/20971825?dopt=AbstractPlus>\]. As the Notch ligands are also membrane bound, cells have to be in close proximity for receptorligand interactions to occur. Cleavage of the intracellular domain (ICD) of activated Notch receptors by γ‐secretase is required for downstream signalling and Notch‐induced transcriptional modulation \[<http://www.ncbi.nlm.nih.gov/pubmed/10206645?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16530044?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9620803?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16530045?dopt=AbstractPlus>\]. This is why γ‐secretase inhibitors can be used to downregulate Notch signalling and explains their anticancer action. One such small molecule is <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7338> \[<http://www.ncbi.nlm.nih.gov/pubmed/19773430?dopt=AbstractPlus>\], although development of this compound has been terminated following an unsuccessful Phase II single agent clinical trial in metastatic colorectal cancer \[<http://www.ncbi.nlm.nih.gov/pubmed/22445247?dopt=AbstractPlus>\].

Aberrant Notch signalling is implicated in a number of human cancers \[<http://www.ncbi.nlm.nih.gov/pubmed/17344417?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24651013?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18079963?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17173050?dopt=AbstractPlus>\], with <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8451> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8453> identified as antibody inhibitors of ligand:receptor binding \[<http://www.ncbi.nlm.nih.gov/pubmed/25388163?dopt=AbstractPlus>\]. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2861><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2859><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2860><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2862>HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7881>, <http://www.uniprot.org/uniprot/P46531><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7882>, <http://www.uniprot.org/uniprot/Q04721><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7883>, <http://www.uniprot.org/uniprot/Q9UM47><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7884>, <http://www.uniprot.org/uniprot/Q99466>CommentsVarious types of activating and inactivating *NOTCH1* mutations have been reported to be associated with human diseases, for example: aortic valve disease \[<http://www.ncbi.nlm.nih.gov/pubmed/16025100?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18593716?dopt=AbstractPlus>\], Adams‐Oliver syndrome 5 \[<http://www.ncbi.nlm.nih.gov/pubmed/25132448?dopt=AbstractPlus>\], T‐cell acute lymphoblastic leukemia (T‐ALL) \[<http://www.ncbi.nlm.nih.gov/pubmed/15472075?dopt=AbstractPlus>\], chronic lymphocytic leukemia (CLL) \[<http://www.ncbi.nlm.nih.gov/pubmed/21642962?dopt=AbstractPlus>\] and head and neck squamous cell carcinoma \[<http://www.ncbi.nlm.nih.gov/pubmed/21798897?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21798893?dopt=AbstractPlus>\].----Notch receptor 4 is a potential therapeutic molecular target for triple‐negative breast cancer \[<http://www.ncbi.nlm.nih.gov/pubmed/25993190?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24403446?dopt=AbstractPlus>\].

### Further reading on Notch receptors {#bph14747-sec-0039}

Arumugam TV *et al*. (2018) Notch signaling and neuronal death in stroke. *Prog. Neurobiol.* **165‐167**: 103‐116 \[<https://www.ncbi.nlm.nih.gov/pubmed/29574014?dopt=AbstractPlus>\]

Borggrefe T *et al*. (2016) The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFβ/BMP and hypoxia pathways. *Biochim. Biophys. Acta* **1863**: 303‐13 \[<https://www.ncbi.nlm.nih.gov/pubmed/26592459?dopt=AbstractPlus>\]

Palmer WH *et al*. (2015) Ligand‐Independent Mechanisms of Notch Activity. *Trends Cell Biol.* **25**: 697‐707 \[<https://www.ncbi.nlm.nih.gov/pubmed/26437585?dopt=AbstractPlus>\]

Previs RA *et al*. (2015) Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. *Clin. Cancer Res.* **21**: 955‐61 \[<https://www.ncbi.nlm.nih.gov/pubmed/25388163?dopt=AbstractPlus>\]

Takebe N *et al*. (2015) Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. *Nat Rev Clin Oncol* **12**: 445‐64 \[<https://www.ncbi.nlm.nih.gov/pubmed/25850553?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=891> {#bph14747-sec-0040}
---------------------------------------------------------------------------

### Overview {#bph14747-sec-0041}

Regulators of G protein signalling (RGS) proteins display a common RGS domain that interacts with the GTP‐bound Gα subunits of heterotrimeric G proteins, enhancing GTP hydrolysis by stabilising the transition state \[<http://www.ncbi.nlm.nih.gov/pubmed/8756726?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9108480?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9417641?dopt=AbstractPlus>\], leading to a termination of GPCR signalling. Interactions through protein: protein interactions of many RGS proteins have been identified for targets other than heteromeric G proteins. Sequence analysis of the 20 RGS proteins suggests four families of RGS: RZ, R4, R7 and R12 families. Many of these proteins have been identified to have effects other than through targetting G proteins. Included here is RGS4 for which a number of pharmacological inhibitors have been described.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=892> {#bph14747-sec-0042}
---------------------------------------------------------------------------

### Overview {#bph14747-sec-0043}

The RZ family of RGS proteins is less well characterized than the other families \[<http://www.ncbi.nlm.nih.gov/pubmed/16765607?dopt=AbstractPlus>\]. It consists of RGS17 (also known as RGSZ2), RGS19 (also known as GAIP) and RGS20 (with several splice variants including RGSZ1 and Ret‐RGS). All members contain an N‐terminal cysteine string motif \[<http://www.ncbi.nlm.nih.gov/pubmed/17183362?dopt=AbstractPlus>\] which is a site of palmitoylation and could serve functions in membrane targeting, protein stability or aid protein‐protein interactions \[<http://www.ncbi.nlm.nih.gov/pubmed/17126529?dopt=AbstractPlus>\]. However, the function in the case of RZ family RGS proteins is not yet fully understood. Members of the RZ family of RGS proteins are the only RGS proteins that have selective GTPase activating‐protein (GAP) activity for Gα~z~, a function that resulted in the name of the family \[<http://www.ncbi.nlm.nih.gov/pubmed/9748279?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15096504?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9748280?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/1347957?dopt=AbstractPlus>\]. However, the members of the RZ family are able to also GAP Gα~i/o~ members with varying selectivity. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2801><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2802><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2803>Common abbreviationRGS17RGS19RGS20HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14088>, <http://www.uniprot.org/uniprot/Q9UGC6><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13735>, <http://www.uniprot.org/uniprot/P49795><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14600>, <http://www.uniprot.org/uniprot/O76081>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=893> {#bph14747-sec-0044}
---------------------------------------------------------------------------

### Overview {#bph14747-sec-0045}

This is the largest family of RGS proteins. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2804><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2808><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2810><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2811>Common abbreviationRGS1RGS2RGS3RGS4HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9991>, <http://www.uniprot.org/uniprot/Q08116><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9998>, <http://www.uniprot.org/uniprot/P41220><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9999>, <http://www.uniprot.org/uniprot/P49796><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10000>, <http://www.uniprot.org/uniprot/P49798>Selective inhibitors------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8033> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/22368763?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7784> (pIC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/21329361?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8034> (pIC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/22368763?dopt=AbstractPlus>\] Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2812><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2813><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2805><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2806><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2807><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2809>Common abbreviationRGS5RGS8RGS13RGS16RGS18RGS21HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10001>, <http://www.uniprot.org/uniprot/O15539><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16810>, <http://www.uniprot.org/uniprot/P57771><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9995>, <http://www.uniprot.org/uniprot/O14921><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9997>, <http://www.uniprot.org/uniprot/O15492><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14261>, <http://www.uniprot.org/uniprot/Q9NS28><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26839>, <http://www.uniprot.org/uniprot/Q2M5E4>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=894> {#bph14747-sec-0046}
---------------------------------------------------------------------------

### Overview {#bph14747-sec-0047}

This family of RGS proteins shows some selectivity for Gai/o proteins. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2815><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2816><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2817><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2814>Common abbreviationRGS6RGS7RGS9RGS11HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10002>, <http://www.uniprot.org/uniprot/P49758><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10003>, <http://www.uniprot.org/uniprot/P49802><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10004>, <http://www.uniprot.org/uniprot/O75916><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9993>, <http://www.uniprot.org/uniprot/O94810>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=895> {#bph14747-sec-0048}
---------------------------------------------------------------------------

### Overview {#bph14747-sec-0049}

The R12 family consists of RGS10, 12 and 14. RGS12 and 14 are large proteins with additional domains that can participate in protein‐protein interactions and other functions. In contrast, RGS10 is a small protein consisting of the RGS domain and small N‐ and C‐termini, similar to members of the R4 family. However, sequence homology of the RGS10 RGS domain clearly places it in the R12 family \[<http://www.ncbi.nlm.nih.gov/pubmed/26123306?dopt=AbstractPlus>\]. The Gα~i/o~‐Loco (GoLoco) motif in RGS12 and 14 has GDI activity (for Guanine nucleotide Dissociation Inhibitor) towards Gα~i1~, Gα~i2~ and Gα~i3~ \[<http://www.ncbi.nlm.nih.gov/pubmed/11387333?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15951850?dopt=AbstractPlus>\]. Through this activity RGS12 and RGS14 can inhibit G protein signaling both by accelerating GTP hydrolysis and by preventing G protein activation. Splice variants of RGS12 and RGS14 also contain membrane targeting and protein‐protein interaction domains \[<http://www.ncbi.nlm.nih.gov/pubmed/11130074?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11771424?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9651375?dopt=AbstractPlus>\]. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2818><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2819><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2820>Common abbreviationRGS10RGS12RGS14HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9992>, <http://www.uniprot.org/uniprot/O43665><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9994>, <http://www.uniprot.org/uniprot/O14924><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9996>, <http://www.uniprot.org/uniprot/O43566>

### Further reading on Regulators of G protein Signaling (RGS) proteins {#bph14747-sec-0050}

Alqinyah M *et al*. (2018) Regulating the regulators: Epigenetic, transcriptional, and post‐translational regulation of RGS proteins. *Cell. Signal.* **42**: 77‐87 \[<https://www.ncbi.nlm.nih.gov/pubmed/29042285?dopt=AbstractPlus>\]

Neubig RR *et al*. (2002) Regulators of G‐protein signalling as new central nervous system drug targets. *Nat Rev Drug Discov* **1**: 187‐97 \[<https://www.ncbi.nlm.nih.gov/pubmed/12120503?dopt=AbstractPlus>\]

Sethakorn N *et al*. (2010) Non‐canonical functions of RGS proteins. *Cell. Signal.* **22**: 1274‐81 \[<https://www.ncbi.nlm.nih.gov/pubmed/20363320?dopt=AbstractPlus>\]

Sjögren B. (2017) The evolution of regulators of G protein signalling proteins as drug targets ‐ 20 years in the making: IUPHAR Review 21. *Br. J. Pharmacol.* **174**: 427‐437 \[<https://www.ncbi.nlm.nih.gov/pubmed/28098342?dopt=AbstractPlus>\]

Sjögren B *et al*. (2010) Thinking outside of the 'RGS box': new approaches to therapeutic targeting of regulators of G protein signaling. *Mol. Pharmacol.* **78**: 550‐7 \[<https://www.ncbi.nlm.nih.gov/pubmed/20664002?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=785> {#bph14747-sec-0051}
---------------------------------------------------------------------------

### Overview {#bph14747-sec-0052}

Although termed 'receptors', the evidence for coupling through conventional signalling pathways is lacking. Initially described as a subtype of opioid receptors, there is only a modest pharmacological overlap and no structural convergence with the G protein‐coupled receptors; the crystal structure of the sigma1 receptor \[<http://www.ncbi.nlm.nih.gov/pubmed/27042935?dopt=AbstractPlus>\] suggests a trimeric structure of a single short transmembrane domain traversing the endoplasmic reticulum membrane, with the bulk of the protein facing the cytosol. A wide range of compounds, ranging from psychoactive agents to antihistamines, have been observed to bind to these sites. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2552><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2553>HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8157>, <http://www.uniprot.org/uniprot/Q99720><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28106>, <http://www.uniprot.org/uniprot/Q5BJF2>Agonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6684> \[<http://www.ncbi.nlm.nih.gov/pubmed/16463398?dopt=AbstractPlus>\] -- Guinea pigSelective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6678> \[<http://www.ncbi.nlm.nih.gov/pubmed/1658302?dopt=AbstractPlus>\], (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6677>--Antagonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6682> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/10096443?dopt=AbstractPlus>\]Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6679> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/7901723?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6680> (pIC~50~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/8566098?dopt=AbstractPlus>\]--Labelled ligands\[<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6683> (Agonist)\[<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6685> (Agonist)Comments--The sigma2 receptor has been reported to be TMEM97 \[<http://www.ncbi.nlm.nih.gov/pubmed/28559337?dopt=AbstractPlus>\], a 4TM protein partner of NPC1, the Niemann‐Pick C1 protein, a 13TM cholesterol‐binding protein.

### Comments {#bph14747-sec-0053}

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1606> also shows activity at opioid receptors. The sigma2 receptor has recently been reported to be <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2553> \[<http://www.ncbi.nlm.nih.gov/pubmed/28559337?dopt=AbstractPlus>\], a 4TM protein partner of NPC1, the Niemann‐Pick C1 protein, a 13TM cholesterol‐binding protein.

### Further reading on Sigma receptors {#bph14747-sec-0054}

Chu UB *et al*. (2016) Biochemical Pharmacology of the Sigma‐1 Receptor. *Mol. Pharmacol.* **89**: 142‐53 \[<https://www.ncbi.nlm.nih.gov/pubmed/26560551?dopt=AbstractPlus>\]

Gris G *et al*. (2015) Sigma‐1 receptor and inflammatory pain. *Inflamm. Res.* **64**: 377‐81 \[<https://www.ncbi.nlm.nih.gov/pubmed/25902777?dopt=AbstractPlus>\]

Rousseaux CG *et al*. (2016) Sigma receptors \[*σ*Rs\]: biology in normal and diseased states. *J. Recept. Signal Transduct. Res.* **36**: 327‐388 \[<https://www.ncbi.nlm.nih.gov/pubmed/26056947?dopt=AbstractPlus>\]

Sambo DO *et al*. (2018) The sigma‐1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction. *Pharmacol Ther* **186**: 152‐167 \[<https://www.ncbi.nlm.nih.gov/pubmed/29360540>\]

Su TP *et al*. (2016) The Sigma‐1 Receptor as a Pluripotent Modulator in Living Systems. *Trends Pharmacol. Sci.* **37**: 262‐278 \[<https://www.ncbi.nlm.nih.gov/pubmed/26869505?dopt=AbstractPlus>\]

Vavers E *et al*. (2019) Allosteric Modulators of Sigma‐1 Receptor: A Review. *Front Pharmacol* **10**: 223 \[<https://www.ncbi.nlm.nih.gov/pubmed/30941035>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=858> {#bph14747-sec-0055}
---------------------------------------------------------------------------

### Overview {#bph14747-sec-0056}

Tubulins are a family of intracellular proteins most commonly associated with microtubules, part of the cytoskeleton. They are exploited for therapeutic gain in cancer chemotherapy as targets for agents derived from a variety of natural products: taxanes, colchicine and vinca alkaloids. These are thought to act primarily through β‐tubulin, thereby interfering with the normal processes of tubulin polymer formation and disassembly. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2638><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2639><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2752><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2641><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2753>HGNC, UniProt<https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20766>, <http://www.uniprot.org/uniprot/Q71U36><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12407>, <http://www.uniprot.org/uniprot/P68366><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20778>, <http://www.uniprot.org/uniprot/P07437><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20772>, <http://www.uniprot.org/uniprot/Q13509><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20771>, <http://www.uniprot.org/uniprot/P68371><https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20773>, <http://www.uniprot.org/uniprot/Q3ZCM7>Inhibitors----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6851> (pIC~50~ 9), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6813> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/21324687?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2770> (Mitotic cell cycle arrest in A431 cells) (pEC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/16377187?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2367> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/16504507?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6798>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6809>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6824>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6785><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8854> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/23895532?dopt=AbstractPlus>\]----

### Further reading on Tubulins {#bph14747-sec-0057}

Arnst KE *et al*. (2019) Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy. *Med Res Rev* **39**: 1398‐1426 \[<https://www.ncbi.nlm.nih.gov/pubmed/30746734>\]

Eshun‐Wilson L. (2019) Effects of alpha‐tubulin acetylation on microtubule structure and stability. *Proc Natl Acad Sci U S A* **116**: 10366‐10371 \[<https://www.ncbi.nlm.nih.gov/pubmed/31072936>\]

Gadadhar S *et al*. (2017) The tubulin code at a glance. *J. Cell. Sci.* **130**: 1347‐1353 \[<https://www.ncbi.nlm.nih.gov/pubmed/28325758?dopt=AbstractPlus>\]

Magiera MM *et al*. (2018) Tubulin Posttranslational Modifications and Emerging Links to Human Disease. *Cell* **173**: 1323‐1327 \[<https://www.ncbi.nlm.nih.gov/pubmed/29856952>\]

Penna LS *et al*. (2017) Anti‐mitotic agents: Are they emerging molecules for cancer treatment? *Pharmacol. Ther.* **173**: 67‐82 \[<https://www.ncbi.nlm.nih.gov/pubmed/28174095?dopt=AbstractPlus>\]
